Bone density, increased

Gonadotropin regnlation Spermatogenesis Sexnal dysfnnction Sexnal restoration and development Protein anabolic effects Increased bone density Increased mnscle mass Increased red blood cell mass... 

Fractures of the spine, wrist, and hips decrease by 50 to 70%, and spinal bone density increases by 5% (24), in those women treated with estrogen within 3 years of the onset of menopause and for 5 to 1 0 years thereafter (5,11,25). The minimum dose required and that which is considered to be standard therapy is 0.625 mg/day of conjugated estrogens (Premarin) however, a 0.3 mg/day dose of esterified estrogen (Estratab) has been shown to be adequate for the prevention of osteoporosis (5). Estrogen replacement therapy is available in several types of formulations, including transdermal patches (Climera, Estraderm, Menostar, or Vivelle). 

Various estimations indicate that nearly twenty million women in America suffer osteoporotic problems. The physiological changes that take place are certainly forms of aging. In one five-year study where ERT compliance was carefully monitored, the bone mineral density increased regardless of the length of treatment or the patient s age when therapy commenced (69). 

PTH has a dual effect on bone cells, depending on the temporal mode of administration given intermittently, PTH stimulates osteoblast activity and leads to substantial increases in bone density. In contrast, when given (or secreted) continuously, PTH stimulates osteoclast-mediated bone resorption and suppresses osteoblast activity. Further to its direct effects on bone cells, PTH also enhances renal calcium re-absorption and phosphate clearance, as well as renal synthesis of 1,25-dihydroxy vitamin D. Both PTH and 1,25-dihydroxyvitamin D act synergistically on bone to increase serum calcium levels and are closely involved in the regulation of the calcium/phosphate balance. The anabolic effects of PTH on osteoblasts are probably both direct and indirect via growth factors such as IGF-1 and TGF 3. The multiple signal transduction... 

Osteoporosis is a common condition, in which bone density is decreased as a consequence of an imbalance between bone formation (osteoblast) and bone loss (osteoclast). This leads to fragile bones, which are at an increased risk for fractures. The term porosis means spongy, which describes the large holes seen in these bones. 

A major regulator of bone metabolism and calcium homeostasis, parathyroid hormone (PTH) is stimulated through a decrease in plasma ionised calcium and increases plasma calcium by activating osteoclasts. PTH also increases renal tubular calcium re-absorption as well as intestinal calcium absorption. Synthetic PTH (1-34) has been successfully used for the treatment of osteoporosis, where it leads to substantial increases in bone density and a 60-70% reduction in vertebral fractures. 

Osteopetrosis (marble bone disease), characterized by increased bone density, is due to inability to resorb bone. One form occurs along with renal tubular acidosis and cerebral calcification. It is due to mutations in the gene (located on chromosome 8q22) encoding carbonic anhydrase II (CAII), one of four isozymes of carbonic anhydrase present in human tissues. The reaction catalyzed by carbonic anhydrase is shown below ... 

The most common adverse effects from inhaled corticosteroids include oropharyngeal candidiasis and hoarse voice. These can be minimized by rinsing the mouth after use and by using a spacer device with metered-dose inhalers. Increased bruising and decreased bone density have also been reported the clinical importance of these effects remains uncertain.1,2,19... 

Peripheral bone mineral density measurements cannot be used for diagnosis because they do not correlate with central measurements. However, they are useful in identifying patients who are candidates for central DXA and who are at increased risk of fracture.5 It also may be useful in patients who have had multiple fractures or in low-risk patients. Additionally, peripheral measurement of bone mineral density generally is less expensive than central DXA and is easily accessible. Instruments used for peripheral bone densitometry are portable, which allows bone density to be measured in pharmacies and health-fair screening booths. 

Excessive doses of thyroid hormone may lead to heart failure, angina pectoris, and myocardial infarction. Allergic or idiosyncratic reactions can occur with the natural animal-derived products such as desiccated thyroid and thyroglobulin, but they are extremely rare with the synthetic products used today. Excess exogenous thyroid hormone may reduce bone density and increase the risk of fracture. 

Low-dose hormone therapy (conjugated equine estrogen 0.45 mg and medroxyprogesterone acetate 1.5 mg/day) has demonstrated equivalent symptom relief and bone density preservation without an increase in endometrial hyperplasia. Whether such lower doses will be safer (cause less venous thromboembolism and breast cancer) remains to be seen. 

Osteoporosis is currently defined as a skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fracture. Bone strength reflects the integration of two main features bone density and bone quality (NIH Consensus 2001). Thus, osteoporosis is a debilitating condition of the skeleton that propends to fractures and is associated with advanced age. The disease has a high prevalence in western countries, as it is a condition associated with advanced age, and it is on the rise since fife expectancy has risen dramatically in the last several decades. It is, therefore, a major public health problem because it not only induces morbidity (fractures and chronic sequelae) with a substantial impact on health-related quality of life, but is also associated with increased mortality (Badia et al. 2001, 2004). 

VanWesenbeeck, L., Cleiren, E., Gram, J., Beals, R.K., Benichou, 0., Scopelliti, D., Key, L., Renton, T., Bartels, C., Gong, Y., Warman, M.L., DeVernejonl, M-C., Bollerslev, J., and VanHnl, W. (2003) Six Novel Missense Mutations in the LDL Receptor-Related Protein 5 (LRP5) Gene in Different Conditions with an Increased Bone Density. American Journal of Human Genetlcsll, 763-771. 

Repeated exposure to excessive concentrations of hydrogen fluoride over a period of years may result in an increased radiographic density of bone and eventually may cause crippling fluorosis (osteosclerosis due to deposition of fluoride in bone)/ The early signs of increased bone density from fluoride deposition are most apparent in the lumbar spine and pelvis and can be detected by X ray. 

Biological monitoring of urinary fluoride concentration provides an indication of total fluoride intake. Data indicate that a postshift urinary fluoride level of less than 8 mg/1, averaged over an extended period of time, will not lead to osteosclerosis, although a minimal or questionable increase in bone density might develop after many years of occupational exposure. ... 

Applications of cation and anion resins are varied and include purification of sugar, identification of drugs and biomacromolecules, concentration of uranium, calcium therapy to help increase the amount of calcium in our bones (i.e., increase the bone density), and use as therapeutic agents for the control of bile acid and gastric acidity. In the latter use, a solid polyamide (Colestid) is diluted and taken with orange juice, which facilitates removal of bile acids from the body. This removal helps the body to produce more bile acid from cholesterol, thus effectively reducing the cholesterol level. 

Decreased bone density In women, long-term levothyroxine therapy has been associated with increased bone resorption, thereby decreasing bone mineral density, especially in postmenopausal women on greater than replacement doses or in women who are receiving suppressive doses of levothyroxine. 

Excess exposure to fluoride results in stained or mottled teeth. This is common in areas where fluoride water levels are above 4 ppm. Chronic elevated fluoride exposure can also result in increased bone density. Fluoride has been used to treat decreased bone density. 

Accumulation of homocysteine and reduced transsulfation of various compounds leads to abnormalities in connective tissue structures that cause altered blood vessel wall structure, loss of skeletal bone density (osteoporosis), dislocated optic lens (ectopia lentis), and increased risk of blood clots. 

---